I agree that this site is using cookies. You can find further informations here.
X
Moehler, M.
~ 300  results:
Search for persons X
?
1

419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as fi..:

Wyrwicz, L.S. ; Shitara, K. ; Moehler, M....
Annals of Oncology.  35 (2024)  - p. S169-S170 , 2024
Link: https://doi.org/10.1016/..
 
?
2

397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo ..:

Moehler, M. ; Oh, D-Y. ; Kato, K....
Annals of Oncology.  35 (2024)  - p. S160-S161 , 2024
Link: https://doi.org/10.1016/..
 
?
3

EORTC stomach cancer PD-L1 biomarker European initiative: t..:

Petrillo, A. ; Oudijk, L. ; Sundar, R....
ESMO Gastrointestinal Oncology.  5 (2024)  - p. 100071 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Advances in the management of hepatobiliary and pancreatic ..:

Fulgenzi, C. ; Garajová, I. ; Moehler, M....
ESMO Gastrointestinal Oncology.  3 (2024)  - p. 100039 , 2024
Link: https://doi.org/10.1016/..
 
?
5

A wind of change in upper gastrointestinal cancers: updates..:

Cammarota, A. ; Siebenhüner, A.R. ; Maqueda, M.A....
ESMO Gastrointestinal Oncology.  3 (2024)  - p. 100035 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Standardized and quality-assured predictive PD-L1 testing i..:

Baretton, Gustavo B. ; Lordick, Florian ; Gaiser, T....
Journal of Cancer Research and Clinical Oncology.  149 (2023)  17 - p. 16231-16238 , 2023
Link: https://doi.org/10.1007/..
 
?
7

Mismatch repair deficiency, chemotherapy and survival for r..:

Stolze, T. ; Franke, S. ; Haybaeck, J....
Journal of Cancer Research and Clinical Oncology.  149 (2022)  3 - p. 1007-1017 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Margetuximab with retifanlimab as first-line therapy in HER..:

Catenacci, D.V.T. ; Kang, Y.-K. ; Yoon, H.H....
ESMO Open.  7 (2022)  5 - p. 100563 , 2022
Link: https://doi.org/10.1016/..
 
?
9

ESMO Congress 2021: highlights from the EORTC gastrointesti..:

Koessler, T. ; Alsina, M. ; Arnold, D....
ESMO Open.  7 (2022)  2 - p. 100392 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Safety and efficacy of HER2 blockade by trastuzumab-based c..:

Catenacci, D.V.T. ; Chung, H.C. ; Shen, L....
ESMO Open.  7 (2022)  1 - p. 100360 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Relevance of baseline carcinoembryonic antigen for first-li..:

Holch, J.W. ; Ricard, I. ; Stintzing, S....
European Journal of Cancer.  106 (2019)  - p. 115-125 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Consensus molecular subgroups (CMS) of colorectal cancer (C..:

Stintzing, S. ; Wirapati, P. ; Lenz, H.-J....
Annals of Oncology.  30 (2019)  11 - p. 1796-1803 , 2019
Link: https://doi.org/10.1093/..
 
?
13

Vaccinia-based oncolytic immunotherapy Pexastimogene Devaci..:

Moehler, M. ; Heo, J. ; Lee, H.C....
OncoImmunology.  8 (2019)  8 - p. , 2019
Link: https://doi.org/10.1080/..
 
?
14

Impact of BRAF and RAS mutations on first-line efficacy of ..:

Stintzing, S. ; Miller-Phillips, L. ; Modest, D.P....
European Journal of Cancer.  79 (2017)  - p. 50-60 , 2017
Link: https://doi.org/10.1016/..
 
?
15

Evaluation of survival across several treatment lines in me..:

Modest, D.P. ; Ricard, I. ; Stintzing, S....
European Journal of Cancer.  84 (2017)  - p. 262-269 , 2017
Link: https://doi.org/10.1016/..
 
1-15